[Effect of Guliu capsule combined with 89Sr therapy on metastatic bone tumor].

OBJECTIVE: To evaluate the therapeutic effects of Guliu capsule (GLC) combined with 89Sr in treating metastatic bone tumors. METHODS: On the basis of random sampling and grouping, 50 patients with metastatic bone tumors were selected to receive combined treatment with GLC and (89)Sr with another 50 patients recruited for (89)Sr treatment alone. The therapeutic effect of the therapies were evaluated according to the relief of ostalgia and quality-of life (QOF), local bone metabolism and hematopoietic function of the bone marrow. RESULTS: The efficacy rate of GLC+89Sr and (89)Sr in relieving ostalgia was 94.0% and 76.0%, and the rate of QOF improvement and stabilization was 94.0% and 74.0%, respectively, both showing significant difference between the two groups (P<0.05). The effect of the two treatment protocols on local bone metabolism and their hemotoxicity were also significantly different (P<0.05, P<0.01, respectively). CONCLUSION: Combined treatment with GLC and (89)Sr is effective for metastatic bone tumor and improves the patient's QOF with enhanced ostalgia relief rate and decreased hemotoxicity.

[Effect of shenqi fuzheng injection for assistance of chemotherapy in treating senile patients with non-small cell lung cancer].

OBJECTIVE: To study the effect of chemotherapy assisted with shenqi fuzheng injection (SFI) on senile patients with non-small cell lung cancer (NSCLC). METHODS: One hundred and twenty old patients with NSCLC were treated with NP chemotherapeutic protocol, to the 60 patients in the treated group among them, additional medication of SFI was started one week before the beginning of chemotherapy. The short-term therapeutic efficacy, long-term survival rate, changes on quality of life (QOL) and immune function of patients, and hematological toxicity of therapy were observed. RESULTS: Difference between the two groups on short-term therapeutic effect, 1- and 2-year survival rate showed no significance (P>0.05), but the 3-year survival rate in the treated group was 26.6%, while that in the control group was 11.7%, showed that the former was higher than the latter. After treatment QOL of the treated group was better than that of the control (P<0.05). Besides, the hematological toxicity and affection on immune function of chemotherapy after treatment in the treated group were all lower than those in the control group showing significant difference (P<0.05). CONCLUSION: SFI has definite toxicity relieving effect on chemotherapy in treating senile NSCLC.